Pancreatic cancer detection kit

By detecting 18 chromosomal instable regions and KRAS mutations related to pancreatic cancer, high-throughput sequencing technology and gene library construction are used to solve the problems of insufficient complexity and sensitivity of existing pancreatic cancer diagnosis methods, and efficient and accurate pancreas Cancer diagnosis.

CN118910264APending Publication Date: 2024-11-08SUZHOU HONGYUAN BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411245093.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-04
Filing Date
2024-09-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing pancreatic cancer diagnosis methods have complexity of results, experience dependence and insufficient sensitivity, resulting in many misdiagnosis and missed diagnosis. The existing molecular diagnostic technology only detects a single indicator and has a low diagnostic accuracy rate.

Method used

By detecting 18 chromosomal instability regions and KRAS mutations related to pancreatic cancer, high-throughput sequencing technology and gene library construction are used, and combined with data analysis, multi-marker combination detection of pancreatic cancer is achieved to improve diagnostic efficiency and accuracy.

Benefits of technology

It significantly improves the diagnostic efficiency and specificity of pancreatic cancer, with a sensitivity of 93.4%, and a specificity of 95.1%, reducing the rate of misdiagnosis and missed diagnosis and providing more accurate diagnostic results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910264A_ABST
    Figure CN118910264A_ABST
Patent Text Reader

Abstract

The invention discloses a pancreatic cancer detection kit, and relates to the technical field of biological detection. The invention also discloses a combination of a chromosome unstable region and gene variation. The combination consists of 1q, 3p 14.3 to 3p 26.2, 3q 24 to 3q 29, 4p, 6p 22.1 to 24.3, 6q, 7p, 8p, 8q, 9p, 9q, 12p, 12q 23.2 to 12q 24.33, 13q, 17p, 18q, 20p 11.23 to 20p 13 and KRAS. The kit for detecting pancreatic cancer comprises the combination, the sensitivity of the kit reaches 93.4%, the specificity reaches 95.1%, the AUC area of an ROC curve relative to pancreatic cancer detection reaches 0.936, and a scientific basis can be provided for clinical early diagnosis of pancreatic cancer and pancreatic infection and formulation of an individualized treatment scheme.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention claims the priority of the invention patent with application number 2024102409312. The name of the prior application is “A pancreatic cancer detection kit” and the application date is March 4, 2024. Technical Field

[0002] The present invention relates to the field of biological detection technology, specifically to the field of molecular detection and diagnosis technology, and more specifically to a pancreatic cancer detection kit. Background Art

[0003] Pancreatic cancer is one of the most malignant tumors and ranks at the forefront of malignant tumor-related deaths in the world. Endoscopic ultrasound (EUS) combines ultrasound imaging with endoscopic technology to improve the sensitivity and specificity of pancreatic cancer diagnosis; in particular, endobronchial ultrasound-guided fine needle aspiration (EUS-FNA) has become the most accurate method for localization and qualitative diagnosis of pancreatic cancer. However, it has many shortcomings. First, its results are divided into 6 diagnostic levels, namely: level I, cannot be diagnosed; level II, no malignancy; level III, atypical; level IV A, neoplastic lesions, benign; level IV B, neoplastic lesions, other; level V, suspected malignancy; level VI, malignant; the interpretation of the results is very complicated. Secondly, its results need to be judged by experienced pathologists, and the interpretation results are affected by experience. Different personnel have very different interpretation results. Third, the sensitivity of EUS-FNA cannot meet clinical needs at present, and there are still some missed diagnoses.

[0004] Molecular diagnosis refers to the technology of making a diagnosis by using molecular biological methods to detect changes in the structure or expression level of genetic material in the patient. Molecular diagnosis is the main method of predictive diagnosis, which can be used for diagnosis of individual genetic diseases as well as prenatal diagnosis. Molecular diagnosis mainly refers to the detection of genes encoding various structural proteins, enzymes, antigens and antibodies, and immune-active molecules related to the disease.

[0005] According to previous studies, genomic instability (GI) is a prominent feature of almost all human cancers, which can lead to genetic aberrations at multiple levels: from single nucleotide changes at the gene level, overall structural changes at the subchromosome level to the loss and gain of entire chromosomes (Yi Q, Chen Q, Liang C, et al. HP1 links centromeric heterochromatin to centromere cohesion in mammals[J]. Embo Reports, 2018: e45484. DOI: 10.15252 / embr.201745484.). Molecular biology studies have shown that tumors accumulate a large number of mutant genes, and potential genomic instability may accelerate the accumulation of these mutations (Cimini D, Howell B, Maddox P, et al. Merotelic Kinetochore Orientation Is a Major Mechanism of Aneuploidy in Mitotic Mammalian Tissue Cells [J]. Journal of Cell Biology, 2001, 153 (3): 517-527. DOI: 10.2307 / 1620404.). The prior art has summarized and defined the characteristics of cancer, and listed genomic instability and mutation as one of the important characteristics of carcinogenesis (Gregan J, Polakova S, Zhang L, et al. Merotelic kinetochore attachment: causes and effects [J]. Trends in cell biology, 2011, 21 (6): 374-381. DOI: 10.1016 / j.tcb.2011.01.003.).

[0006] Chromosomal instability (CIN) is the main type of genomic instability and is defined as a higher-than-normal rate of mis-segregation of entire chromosomes or chromosome fragments during mitosis (Cimini D, Wan X, Hirel CB, et al. Aurora kinase promotes turnover of kinetochoremicrotubules to reduce chromosome segregation errors. [J]. CURRENT BIOLOGY, 2006. DOI: 10.1016 / j.cub.2006.07.022.). Some researchers believe that CIN describes a dynamic state, including the gain or loss of whole chromosomes or large fragments (aneuploidy), structural rearrangements and focal aberrations, and is therefore the main mediator of aneuploidy and intratumor heterogeneity (Musacchio A. The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics [J]. Current biology: CB, 2015, 25 (20): R1002-R1018. DOI: 10.1016 / j.cub.2015.08.051.). Studies have found that aneuploidy (a state of abnormal chromosome number) is often accompanied by chromosomal instability, and highly aneuploid cancers are characterized by a large number of structural and numerical DNA copy number changes that alter the expression of most genes located in these regions. Related studies have shown that CIN is mainly caused by chromosomal instability gene mutations that maintain the integrity of the cell genome (Yuji, Tanno, Hiroaki, et al. The innercentromere-shugoshin network prevents chromosomal instability. [J]. Science (New York, NY), 2015. DOI: 10.1126 / science.aaa2655.).Currently, there is increasing evidence that CIN is associated with the occurrence of solid tumors, and its clinical importance is also emphasized by its association with various types of cancer, such as breast cancer (Zhao Na. Relationship between genetic instability of chromosome 16q, 17p and the occurrence of breast cancer [D]. Guizhou Medical University, 2017.), lung cancer (Yao Ning, Luo Rui, Wu Qian, et al. Analysis of the correlation between chromosomal instability and pathological type and prognosis of patients with early lung cancer [J]. Medical Frontier, 2023, 13(28): 47-49.), colon cancer (Li Hong, Wan Jun, Li Yuan, et al. Study on loss of heterozygosity of chromosome 12p12-13 in colon cancer of Chinese [J]. Chinese Journal of Medical Genetics, 2005, 22(6): 4. DOI: 10.3760 / j.issn:1003-9406.2005.06.026.), etc.

[0007] The following molecular diagnostic technologies related to pancreatic cancer are disclosed in the existing patent database:

[0008] Chinese patent CN202210336170.1 discloses the application of reagents and kits for detecting the expression level of chromosome 10 open reading frame 81 (C10orf81), specifically involving the application of a reagent for detecting the expression level of C10orf81 in the preparation of a preparation for auxiliary diagnosis of pancreatic cancer and / or prognosis judgment of pancreatic cancer patients, and a kit for auxiliary diagnosis of pancreatic cancer and / or prognosis judgment of pancreatic cancer patients. The clinical sample test results of this invention showed that the expression of C10orf81 in pancreatic cancer was significantly higher than that in adjacent tissues; and high expression of C10orf81 was not conducive to the overall survival of pancreatic cancer patients. Reagents for detecting changes in the expression of this gene can be used for the prognosis, diagnosis, and treatment of pancreatic cancer. However, it only detects one indicator, and its diagnostic accuracy is relatively low.

[0009] Chinese patent CN202010600228.X discloses a probe composition, a kit and an application for detecting the number of human chromosomes. The probe composition disclosed in the invention targets a first probe combination of the centromere of human chromosome 8 and a second probe combination targeting the centromere of human chromosome 17. The probe composition can detect the number of human chromosomes 8 and 17. The probe composition can easily enter cells and hybridize with the target area, with high hybridization signal intensity and low signal-to-noise ratio. The invention diagnoses pancreatic cancer by detecting abnormal number of chromosome 8, but as described in the invention, diseases with abnormal number of chromosome 8 include myelodysplastic syndrome, gastric cancer, pancreatic cancer and lung cancer, and the specificity of diagnosing pancreatic cancer using this method is not strong.

[0010] In summary, the current diagnosis of pancreatic cancer still needs to be further improved. The present invention is based on high-throughput sequencing technology, by detecting chromosome variations including chromosome arms 1q, 3p14.3-3p26.2, 3q24-3q29, 4p, 6p22.1-24.3, 6q, 7p, 8p, 8q, 9p, 9q, 12p, 12q23.2-12q24.33, 13q, 17p, 18q, 20p11.23-20p13 and KRAS mutations, and using a variety of trace clinical residual samples including puncture tissue, paraffin sections, pancreatic cyst fluid, bile, etc., pancreatic cancer is detected, which significantly improves the diagnostic efficiency of pancreatic cancer, is beneficial to improving the survival rate of pancreatic cancer, and reducing the mortality rate. The present invention helps to solve the clinical problems of pancreatic cancer diagnosis and treatment. Summary of the invention

[0011] The purpose of the present invention is to provide a combination of chromosomal unstable regions and gene mutations, which automatically analyzes whether 18 targets are mutated through library construction and sequencing, makes it easy to interpret the test results, and significantly improves the diagnostic efficiency of pancreatic cancer.

[0012] The numbering of the chromosomes and gene unstable regions involved in the present invention is defined according to the conventional numbering rules in the art. For example, the unstable region 3q refers to the long arm of chromosome 3, and the unstable region 7p refers to the short arm of chromosome 7 in the conventional rules in the art.

[0013] Terminology explanation:

[0014] In the present invention, copy number variations (CNVs) refer to deletions, amplifications and insertions of large fragments. As described herein, CNVs include, but are not limited to, any type of structural changes that can affect the target site for copy number determination, including, but not limited to, duplication, deletion, insertion, repetition, substitution, etc. The copy number difference between samples is usually determined by "relative quantification". Relative quantification is used to report the copy number of the target site or chromosome found in the test sample relative to one or more reference sites or "calibration samples". With regard to the use of calibrator samples, the term "relative to" refers to comparison with the copy number of the target site or chromosome where the target site is found in the calibrator sample. A "calibrator sample" is a biological sample that usually has a known karyotype, and the user can use one or more reference positions or calibration samples as needed. The one or more reference sites may be the same or different and may be present in the test sample or the calibration sample.

[0015] In the present invention, chromosomal instability (CIN) refers to the abnormality of chromosome quantity and structure caused by chromosome segregation errors. It should be understood that variations and abnormalities occur so that the number or composition of chromosomes in a sample can change. In fact, the methods described herein are intended to detect such variations and abnormalities.

[0016] In the present invention, gene variation includes changes in the base pair composition or arrangement order of the gene structure.

[0017] In the present invention, "FFPE" refers to formalin fixed paraffin embedded samples (FFPE), which is a standard method for preserving clinical tissue samples. It has the characteristics of large storage capacity, high stability and complete follow-up information, and is suitable for conducting retrospective clinical studies. When the method of the present invention is used for diagnosis, those skilled in the art can select the sample type according to actual conditions. For clinical instant diagnosis, freshly collected samples can be selected. FFPE is an optional sample form.

[0018] In the present invention, "ERCP" generally refers to endoscopic retrograde cholangiopancreatography, which is one of the main means of minimally invasive treatment of bile and pancreatic diseases. It is a general term for inserting an endoscope into the descending duodenum through the mouth, introducing a special instrument into the bile duct or pancreatic duct through the duodenal papilla, injecting contrast agent for imaging under X-ray fluoroscopy, introducing a sub-endoscope / ultrasound probe for observation, collecting exfoliated cells / tissues, etc., to complete the diagnosis of bile and pancreatic diseases, and implementing corresponding interventional treatments based on the diagnosis. For some bile duct diseases such as bile duct stones and bile duct stenosis, corresponding treatments can be performed under endoscopy. ERCP technology has developed from a diagnostic technology to one of the important technologies for minimally invasive treatment of bile duct and pancreatic diseases. Clinical samples used for diagnosis by the technology of the present invention can also be obtained through ERCP.

[0019] In the present invention, "PTCD" generally refers to percutaneous transhepatic biliary drainage, which is a technical means of placing a catheter in the bile duct percutaneously and transhepatically under imaging technology. For many biliary diseases, PTCD is the preferred treatment option and can also be a palliative treatment method. Patients with biliary stones or tumors may have poor liver function, jaundice, low plasma protein, poor coagulation and immune function, and even cholangitis, pancreatitis and other manifestations due to cholestasis, which may delay the operation time and affect the results of the operation. Preoperative bile drainage methods such as PTCD can relieve cholestasis, improve liver function, regulate coagulation and immune function, and reduce preoperative preparation time. In this process, the collection of clinical test samples can be achieved. It is a preferred method of the present invention.

[0020] In the present invention, "pancreatic puncture" refers to the use of a puncture needle to pierce the pancreas and extract fluid or pancreatic tissue for pathological biopsy. Pancreatic puncture biopsy technology requires the assistance of image guidance for operation, and commonly used image guidance methods include ultrasound, CT, MRI, etc. Among them, endoscopic ultrasound-guided fine needle aspiration / biopsy (EUS-FNA / FNB) is currently the most commonly used and most accurate method. Pancreatic puncture mainly includes two types: fine needle aspiration biopsy (fine needle aspiration, FNA) and fine needle biopsy (fine needle biopsy, FNB). FNA performs cytological examination by aspirating cell fluid, while FNB performs histological examination by taking out tissue samples. The present invention generally achieves diagnosis through FNB, but in some cases it may also be achieved through FNA.

[0021] The terms used in the present invention are only used for the purpose of describing specific embodiments and are not intended to limit the present invention. As used in the present invention, the singular forms "a", "an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, with respect to the terms "include", "including", "having", or variations thereof used in the specific embodiments and / or claims, such terms are intended to be included in a manner similar to the term "comprising".

[0022] To achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:

[0023] On the one hand, the present invention provides a combination of chromosomal unstable regions and gene variations, wherein the combination consists of 1q, 3p14.3-3p26.2, 3q24-3q29, 4p, 6p22.1-24.3, 6q, 7p, 8p, 8q, 9p, 9q, 12p, 12q23.2-12q24.33, 13q, 17p, 18q, 20p11.23-20p13 and KRAS.

[0024] Specifically, the chromosomal instability includes the copy number variation of the entire chromosome or chromosome fragment.

[0025] More specifically, the copy number variation includes deletion and amplification.

[0026] In the present invention, the deletion and amplification refer to the loss or increase of a fragment on the chromosome of an organism, and the gene located in this fragment will also be lost after the deletion. It may be related to genetic factors, chemical factors, physical factors, biological factors, etc. The prior art records that chromosome deletion and amplification may lead to a variety of diseases. Pancreatic cancer has a high frequency of chromosomal changes. The most reported are the deletion of chromosomes 9p, 13q, 17p, and 18q, and the amplification of chromosomes 7q, 8q, 12p, 19q and 20q; and the chromosome instability of 6 pancreatic cancer cell lines is recorded. Common chromosome partial deletions include 10p, 15p, 16p, 21p, etc., and common chromosome fragment amplifications include 5p, 12q, etc. (Yang Zhimei. Study on the chromosome characteristics of Chinese pancreatic cancer cell lines [D]. Tsinghua University School of Medicine, 2009. DOI: 10.7666 / d.Y2123306.). Some documents also disclose other sites, such as the FHIT gene located on chromosome 3p14.2, which may be related to the diagnosis of pancreatic cancer. Pancreatic cancer samples have abnormal transcription and expression loss of the FHIT gene (Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. [J]. Cell, 1996, 84(4): 587-97. DOI: 10.1016 / S0092-8674(00)81034-X). In fact, based on the massive amount of related chromosomal instability reports published, those skilled in the art can screen some combinations for the diagnosis of pancreatic cancer to a certain extent, but such results are basically accidental, and there is no definite direction for the development of specific diagnostic marker combinations.

[0027] The present invention constructs a gene library and combines it with data analysis for a specific chromosomal instability target combination: 1q, 3p14.3-3p26.2, 3q24-3q29, 4p, 6p22.1-24.3, 6q, 7p, 8p, 8q, 9p, 9q, 12p, 12q23.2-12q24.33, 13q, 17p, 18q, 20p11.23-20p13, and finds the feasibility and excellent effect of using the combination in combination with gene variation to diagnose pancreatic cancer.

[0028] In the present invention, the "gene library" is a library that is used to separate and sequence the DNA sequences of certain specific genes in a species, tissue or cell. This library is mainly transcribed from mRNA using methods such as cDNA (complementary DNA) or PCR (Polymerase Chain Reaction) to study the structure, function, expression and regulation of the gene. Typical gene libraries include EST (Expressed Sequence Tag) libraries and cDNA libraries. Establishing and using a gene library is an effective means of isolating genes, especially isolating genes of higher eukaryotic organisms.

[0029] The data analysis described in the present invention includes but is not limited to: analysis of library fragment size, analysis of library mass concentration, calculation of molar concentration, sequence alignment of sequencing data, chromosome variation analysis, gene point mutation analysis, etc. For the specific methods and software operations of these data analyses, in theory, those skilled in the art can implement specific operation procedures based on the degree of disclosure of the prior art, and can know that the conventional selection of these technical means will not cause significant differences in the final results. As an example, the specific embodiment of the present invention provides the use of the Agilent BioAnalyzer biochip analysis system to analyze the fragment size; using dsDNA HS Assay Kit measures the mass concentration of the library; the molar concentration of the library is calculated by the mass concentration and the fragment size; the sequencing data is aligned using the BWA software; after the alignment is completed, the chromosome variation is analyzed using CNVkit to obtain the chromosome analysis results; the point mutation is analyzed using the GATK software to obtain the gene mutation analysis results. Those skilled in the art know that with the development level of the prior art, the basic data for specific analysis can still be obtained by equivalently replacing these technical means. For example, for the analysis of library fragment size, agarose electrophoresis, Bioptic Qsep series analysis system, etc. can also be selected; for the analysis of library mass concentration, nanodrop ultraviolet spectrophotometer, etc. can also be selected; for sequencing data sequence alignment, Bowtie2, SOAP2, etc. can also be selected; for chromosome variation analysis, CNVnator, GISTIC2.0, etc. can also be selected, and for gene point mutation analysis, varscan2, SomaticSniper, etc. can also be selected. The present invention aims to analyze chromosome instability and gene variation. These data acquisition methods are objective to a certain extent and close to the actual situation, so they have certain substitutability for the analysis results.

[0030] Specifically, the genetic variation includes KRAS mutation.

[0031] The KRAS mutation described in the present invention refers to a mutation occurring on the KRAS gene (Kras, K-ras). The application of the KRAS gene in the diagnosis of pancreatic cancer has been partially disclosed in the prior art, such as:

[0032] "Zheng Zhujia, Li Changfu, Han Jiwu. The role of endoscopic ultrasound-guided fine needle aspiration biopsy combined with K-ras gene detection in the diagnosis of pancreatic cancer[J]. Journal of Harbin Medical University, 2011,

[0033] 45(2):3.DOI:10.3969 / j.issn.1000-1905.2011.02.021." It was recorded that there was a significant difference in the concentration of K-ras in the serum and EUS-FNA biopsies of pancreatic cancer patients. The positive detection rate of K-ras in EUS-FNA biopsies of pancreatic cancer patients reached 85.96%; the concentration of K-ras in the biopsy was higher than that in the serum, P<0.05. This shows that the concentration of K-ras has a certain value in the diagnosis of pancreatic cancer. In the prior art, it is also disclosed that: paraffin-embedded tissue (with higher operation requirements) K-ra s gene 12 codon point mutation and K-ras protein expression; analyze the diagnostic efficacy of K-ras gene mutation and protein expression detection, its relationship with the clinical pathological characteristics of pancreatic cancer, and the correlation between K-ras gene mutation and protein expression. Among 31 pancreatic cancer patients, 25 cases (80.6%) (25 / 31) showed positive K-ras gene mutation in paraffin-embedded tissues; 27 cases (87.1%) showed positive K-ras protein expression, but other literatures also disclosed that K-ras gene point mutations can exist in pancreatic cancer and some benign pancreatic lesions (Uehara H, Nakaizumi A, Baba M, et al. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. [J]. American Journal of Gastroenterology, 1996,

[0034] 91(8):1616.DOI:http: / / dx.doi.org / .). For some specific mutations, the prior art also discloses that K-ras gene point mutations can exist in pancreatic cancer and some benign pancreatic lesions, but the mutation amounts are different (Chen Xingling, Zhu Xuan, Zhang Kunhe. Diagnostic value of K-ras gene point mutations for pancreatic cancer [J]. Gastroenterology, 2003, 8(4):3.DOI:10.3969 / j.issn.1008-7125.2003.04.005.). It can be seen from the above prior art that there is still a lot of room for improvement in the form (specific mutation type, mutation amount) of KRAS mutations used to diagnose pancreatic cancer and avoid misdiagnosis (including but not limited to misdiagnosis of pancreatitis, pancreatic cysts, benign pancreatic lesions, etc.).

[0035] In some specific embodiments of the present invention, the gene variation is the detection of KRAS gene variation including mutations occurring at the three amino acid positions G12, G13, and Q61 on the amino acid sequence encoded by the KRAS gene. When the mutation frequency exceeds 1%, it is determined to be a tumor, otherwise it is determined to be a non-tumor.

[0036] Specifically, the detection method of chromosomal unstable regions and gene mutations described in the present invention is selected from one or more of second-generation sequencing, chip method, comparative genomics, third-generation sequencing, and fourth-generation sequencing.

[0037] Preferably, the method for detecting chromosomal unstable regions and gene mutations is next generation sequencing.

[0038] As mentioned above, the above sequencing methods are objective to a certain extent and close to the actual situation. Therefore, they have certain substitutability for the analysis results. The specific method adopted in the present invention is only one of the implementation forms.

[0039] In yet another aspect, the present invention provides use of a reagent for detecting the above-mentioned chromosomal unstable region and gene variation in the preparation of a reagent or kit for detecting, screening, diagnosing or evaluating the prognosis of pancreatic cancer.

[0040] Alternatively, it can be understood that the present invention provides the use of the above-mentioned chromosomal unstable regions and gene variations in the detection, screening, diagnosis or prognosis of pancreatic cancer.

[0041] The pancreatic cancer may be hereditary or non-hereditary.

[0042] The detection can be used to distinguish pancreatic cancer tissues or cells, and may be a non-disease diagnosis application or a disease diagnosis application. The detection of specific tissues or cells may be able to infer the type of disease.

[0043] The screening targets samples that have already developed suspected symptoms of pancreatic cancer. Its purpose is prevention, that is, to conduct genetic screening on healthy individuals and to determine, to a certain extent, the risk of the corresponding disease that may occur in the later stage. The specific criteria for such risk determination can be determined by those skilled in the art based on the actual results recorded in this application, such as determining the critical value of screening risk determination based on the ROC curve provided in this application.

[0044] The diagnosis is generally aimed at samples that have already shown suspected symptoms of pancreatic cancer. This diagnosis can be used as an auxiliary means in combination with clinical means for confirmation, which can largely avoid misdiagnosis and missed diagnosis, especially in cases where it is well known in the art that the probability of misdiagnosis or missed diagnosis of pancreatic cancer is high, such as the examples in the literature cited above.

[0045] The prognostic evaluation is aimed at pancreatic cancer patients after surgery, radiotherapy, chemotherapy or drug treatment, and determines whether there are micro-lesions remaining in the patients after treatment, thereby evaluating the patients' treatment prognosis.

[0046] In some areas understood in the art, "sample" and "subject" have equivalent meanings and generally refer to any organism used in the methods of the present disclosure. In some instances, the subject is a human, a mammal, a vertebrate, an invertebrate, a eukaryote, an archaea, a fungus, or a prokaryote. In some cases, the subject may be non-human. The subject may be alive or dead. The subject may be a patient. For example, the subject may have a disease (or be suspected of having a disease) and / or be in the care of a medical practitioner. The subject may be an individual who is undergoing treatment and / or diagnosis of a health or medical condition. The subject and / or family member may be related to another subject (e.g., sister, brother, mother, father, nephew, niece, girl, uncle, grandfather, great-grandfather, cousin) used in the methods of the present disclosure.

[0047] As used herein, the term "sample" generally refers to a biological sample.

[0048] In yet another aspect, the present invention provides a kit for detecting, screening, diagnosing or evaluating the prognosis of pancreatic cancer, wherein the kit comprises reagents for detecting the above-mentioned combination of chromosomal unstable regions and gene mutations.

[0049] Preferably, the kit includes reagents for constructing a sequencing library;

[0050] Further preferably, the reagents for constructing the sequencing library are selected from one or more of a buffer, an enzyme, a library adapter, a nucleic acid extraction reagent, and a nucleic acid purification reagent.

[0051] Still more preferably, the enzyme is selected from one or more of a fragmentation enzyme, a DNA polymerase, and a DNA ligase.

[0052] Still more preferably, the nucleic acid extraction reagent includes but is not limited to tissue DNA extraction and purification reagent.

[0053] Still more preferably, the nucleic acid purification reagents include but are not limited to purification magnetic beads and purification aids.

[0054] Preferably, the kit further comprises one or more of a positive reference substance and a negative reference substance.

[0055] Further preferably, the positive reference is a cell line mixed with the above-mentioned 17 chromosomal unstable regions and gene mutations;

[0056] Further preferably, the negative reference is a cell line without chromosome variation and gene mutation.

[0057] In the present invention, the positive reference and the negative reference can be used for the quality evaluation of the kit. The quality evaluation can be whether the diagnosis can be completed, the stability of the diagnosis, etc.

[0058] Preferably, the kit also includes sequencing primers.

[0059] The sequencing primers can be routinely selected or designed by those skilled in the art without departing from the essence of the present invention, that is, PCR primers designed for the specific combination of the present invention are used for the construction of a gene library and can accurately determine the marker combination defined by the present invention, and all such schemes are within the scope of protection of the present invention.

[0060] Preferably, the present invention provides a method for using the above kit, comprising the following steps:

[0061] (1) Extracting human genomic DNA;

[0062] (2) Construction of genomic library;

[0063] (3) Detect 17 chromosomal unstable regions and 1 gene mutation in the samples;

[0064] (4) If any of the above 18 targets are mutated, it is diagnosed as pancreatic cancer; otherwise, it is non-tumor (pancreatic cancer).

[0065] Preferably, the human genomic DNA is extracted from the following tissues or samples: pancreatic cyst fluid, fresh pancreatic tissue, paraffin sample of pancreatic tissue, bile and cell sample.

[0066] The sampling methods of the pancreatic cyst fluid, fresh pancreatic tissue, bile and cell samples include but are not limited to: surgery and puncture.

[0067] The sample obtained by the puncture may be a puncture flushing fluid.

[0068] In some embodiments, the bile can be sampled by ERCP or PTCD.

[0069] The preparation method of the pancreatic tissue paraffin sample (FFPE) can refer to the method in the prior art, such as: the sample size is recommended to be 15mm×15mm×5mm, and the sample should be taken as soon as possible, because the ex vivo pancreatic tissue is prone to autolysis and the structure is destroyed. Fix immediately after sampling; fix the fixative with 10% alkaline formaldehyde solution for 24 hours, and add AAF solution to supplement the fixation for 20 minutes before tissue dehydration; dehydration: the steps are as follows: 70% ethanol and 80% ethanol for 1 hour each, then 95% ethanol for two times for 2 hours each, 100% ethanol for two times for 40 minutes each, and finally n-butanol for three times for 2 hours each. Embedding and sectioning: three times of wax immersion at 60℃ for a total of 4 hours, and the thickness of the section is recommended to be 3-4μm; dewaxing: two times of xylene for 10 minutes each, two times of anhydrous ethanol for 5 minutes each, 95% ethanol for 5 minutes, 80% ethanol for 2 minutes, 70% ethanol for 1 minute, and finally washed with water; staining: conventional HE staining operation is sufficient, and finally fixed and sealed. In fact, those skilled in the art can prepare the samples according to any disclosure of the prior art, and currently no difference in the detection results of the present invention caused by the preparation method of the paraffin samples has been found.

[0070] In some embodiments, a puncture wash fluid of pancreatic tissue is selected.

[0071] Specifically, the detection method of chromosomal unstable regions and gene mutations is selected from one or more of second-generation sequencing, chip method, comparative genomics, third-generation sequencing, and fourth-generation sequencing.

[0072] More specifically, the method for detecting chromosomal unstable regions and gene mutations is next-generation sequencing.

[0073] In yet another aspect, the present invention provides use of the above-mentioned combination of chromosomal unstable regions and gene mutations in the preparation of drugs for treating or assisting in the treatment of pancreatic cancer.

[0074] Preferably, the drug may further include a pharmaceutically acceptable carrier.

[0075] Further preferably, the pharmaceutically acceptable carrier can be selected from one or more of excipients, buffers, emulsifiers, stabilizers, diluents, binders, preservatives, and lubricants.

[0076] Preferably, the dosage form of the drug includes but is not limited to powder, tablet, pill, granule, capsule, solution, emulsion, suspension or oil.

[0077] In yet another aspect, the present invention provides a method for diagnosing pancreatic cancer, wherein the method comprises detecting the above-mentioned chromosomal unstable regions and gene mutations.

[0078] Specifically, the detection method of chromosomal unstable regions and gene mutations is selected from one or more of second-generation sequencing, chip method, comparative genomics, third-generation sequencing, and fourth-generation sequencing.

[0079] More specifically, the method for detecting chromosomal unstable regions and gene mutations is next-generation sequencing.

[0080] Preferably, the test sample is selected from one or more of pancreatic cyst fluid, fresh pancreatic tissue, paraffin sample of pancreatic tissue, bile, and cell sample.

[0081] The beneficial effects of the present invention are:

[0082] The present invention uses the second-generation sequencing technology to analyze the chromosomal instability information of pancreatic cancer, screens out 17 chromosomal unstable regions and 1 gene that are suitable for characterizing pancreatic cancer, and provides a specific diagnostic method. This method can provide a scientific basis for the early clinical diagnosis of pancreatic cancer and pancreatic infection and the formulation of individualized treatment plans.

[0083] The present invention can use a variety of clinical samples for detection, including pancreatic cyst fluid, fresh pancreatic tissue, pancreatic tissue paraffin samples, bile and cell samples, and automatically analyze through library construction and sequencing. According to the analysis results, if there are 18 target mutations of the present invention, it is judged as pancreatic cancer, otherwise it is judged as non-tumor. The method is simple and clear, and the test results are easy to interpret, which can provide clear clinical diagnostic information and solve the confusion caused by unclear cytopathological test results to the clinic. The detection sensitivity reaches 93.4%, the specificity reaches 95.1%, and the AUC area of ​​the ROC curve for pancreatic cancer detection reaches 0.936, which has good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0084] Figure 1 This is a chromosome region variation detection diagram; chromosome 3p14.3-3p26.2 is missing in the diagram.

[0085] Figure 2 This is a chromosome region variation detection diagram; chromosome 3q24-3q29 is amplified in the diagram.

[0086] Figure 3 This is a chromosome region variation detection diagram; chromosome 4p is missing in the diagram.

[0087] Figure 4 This is a chromosome region variation detection diagram; chromosome 6p22.1-24.3 is amplified in the diagram.

[0088] Figure 5 This is a chromosome region variation detection diagram; chromosome 9p is missing in the diagram.

[0089] Figure 6 This is a chromosome region variation detection diagram; chromosome 12q23.2-12q24.33 is missing in the diagram.

[0090] Figure 7 This is a chromosome region variation detection diagram; chromosome 13q is missing in the diagram.

[0091] Figure 8 This is a chromosome region variation detection diagram; chromosome 18q is missing in the diagram.

[0092] Fig. 9 This is a chromosome region variation detection diagram; chromosome 20p11.23-20p13 is missing in the diagram.

[0093] Fig.10 This is the result of KRAS mutation detection; the KRAD mutation in the figure is p.G13D. This figure is a screenshot of the software interface, and some unclear details do not affect the result determination.

[0094] Fig.11 It is the ROC curve diagram of 18 targets of the present invention. DETAILED DESCRIPTION

[0095] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.

[0096] In the present invention, "Zscore" is a z score, also known in the art as a z-score, also known as a standard score (standard score), which is the process of dividing the difference between a number and the mean by the standard deviation. In statistics, the Zscore is the signed number of the standard deviation of the value of an observation or data point above the mean of the observed or measured value. In this article, "Zscore", "Zscores value" and "scores value" have the same meaning.

[0097] The prior art document "Chiu RWK, Chan KCA, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma [J]. Proceedings of the National Academy of Sciences, 2009, 105 (51): 20458-20463. DOI: 10.1073 / pnas.0810641105." first proposed the Z-score detection method and analyzed the influence of CV and GC content on the accuracy of Z value discrimination. On this basis, “[1] Chen EZ, Chiu RWK, Sun H, et al. Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing [J]. PLoS ONE, 2011, 6(7): e21791. DOI: 10.1371 / journal.pone.0021791.” improved the z-score detection method in 2008 for chromosomes 13 and 18 by using the sequence number after GC correction for Z-score discrimination. “Yuval B, Speed ​​TP. Summarizing and correcting the GC content bias in high-throughput sequencing [J]. Nucleic Acids Research, 2012, 40(10): e72-e72. DOI: 10.1093 / nar / gks001.” further optimized and proposed a more effective GC correction method. The present invention uses the improved method of Yuval B as an example.

[0098] In the present invention, the diagnosis of pancreatitis, pancreatic cysts, and benign pancreatic masses can be achieved by conventional methods in the art, such as:

[0099] Pancreatitis meets the following four criteria: 1. Typical clinical manifestations, such as upper abdominal pain or nausea and vomiting, accompanied by upper abdominal tenderness or peritoneal irritation signs; 2. Increased pancreatic enzyme levels in serum, urine or peritoneal puncture fluid; 3. Image examination (ultrasound, CT) showing pancreatic inflammation or surgical findings or autopsy pathological examination confirming pancreatitis lesions; 4. Other lesions with similar clinical manifestations can be excluded.

[0100] Pancreatic cysts can be diagnosed by finding echo-free areas in the pancreatic tissue through B-ultrasound examination or low-density shadows through CT or MRI examinations;

[0101] Benign pancreatic masses can be distinguished by differences in tumor size, tumor growth rate, tumor marker levels, jaundice, and pain properties: 1. Tumor size: Imaging examinations can be used to determine the size of the tumor. Benign pancreatic tumors usually grow slowly and are small in size; while malignant tumors may be larger and gradually increase in size. 2. Tumor growth rate: Observing the growth rate of the tumor can help distinguish between benign and malignant. Benign tumors generally grow more steadily or slowly; while malignant tumors tend to grow rapidly. 3. Tumor marker levels: Testing for specific proteins in the blood, such as CA19-9, can assist in diagnosis. Under normal circumstances, benign pancreatic diseases do not cause abnormal increases in these proteins; while malignant lesions may cause their concentrations to increase. 4. Jaundice: Monitoring bilirubin and transaminase levels can help assess whether jaundice occurs. Some pancreatic cancer patients may experience mild to moderate jaundice, but benign masses rarely cause significant jaundice. 5. Pain properties: Describe the location, degree, and impact of pain on daily life. Pancreatic inflammatory masses are mostly persistent dull pain in an irregular location, sometimes radiating to the lower back and more obvious at night; while the abdominal pain caused by pancreatic pseudocysts is often persistent bloating and pain located in the left upper abdomen, which can be relieved by diet.

[0102] In the present invention, "sample" generally refers to a biological sample, which may include any sample containing cells or cell materials, particularly cells, ascites, swabs, tissue fluids, organ needle biopsies, fixed tissue samples, tissue sections from fixed or non-fixed tissue samples, particularly frozen sections and paraffin sections, particularly formalin-fixed paraffin sections, tumor materials, biopsy samples, blood samples, particularly whole blood or blood fractions, cell suspensions and all samples containing cell components in the broadest sense, the cell components being intended to include both intact cells and cell components. In addition, "sample" may also include other biological materials containing nucleic acids, such as serum or plasma, secretions, cerebrospinal fluid, bile, lymph or urine. They may also be nucleic acid-containing materials derived from biochemical or biotechnological processes that must then be purified.

[0103] Basic Example 1 Genomic DNA Extraction

[0104] The kit used in this example was purchased from QIAGEN (Cat. No. 80204).

[0105] a. For eligible individuals, transfer 10 mL of bile sample into a 10 mL centrifuge tube and centrifuge at 1600 g for 10 min. Pour off the supernatant carefully and discard the remaining supernatant carefully with a pipette.

[0106] b. Add 350 μL 1× Buffer RL / DTT to a new 1.5 mL centrifuge tube and carefully pump the lysis buffer at least 5 times with a disposable 20-gauge syringe to break up the cells.

[0107] c. Place the DNA purification column in a 2 mL collection tube. Transfer the cell lysate to the gDNA filter column. Centrifuge at 14,000 g for 2 min.

[0108] d. Place the DNA purification column in a 2 mL collection tube. Add 500 μL of Buffer DW1 to the column and let stand for 2 minutes. Centrifuge at 10,000 g for 30-60 seconds.

[0109] e. Discard the effluent and put the column back into the collection tube. Add 500 μL Buffer RW2 to the column. Centrifuge at 10,000 g for 30-60 seconds.

[0110] f. Discard the effluent and put the column back into the collection tube. Add 500 μL Buffer RW2 to the column. Centrifuge at 10,000 g for 30-60 seconds.

[0111] g. Discard the flow-through, put the column back into the empty collection tube, and centrifuge at 13000g for 2 minutes.

[0112] h. Place the DNA column in a 1.5 mL centrifuge tube. Add 30-50 μL of nuclease-free water preheated to 65°C to the center of the column membrane. Let stand at room temperature for 3 minutes. Centrifuge at 13,000 g for 1 minute.

[0113] i. Discard the DNA column and store the DNA at 2-8°C or -20°C.

[0114] Basic Example 2 Gene Library Construction

[0115] The library construction kit in this example was purchased from NEB, item number: E7645S; the magnetic beads were purchased from Beckman, item number: A63882. Unless otherwise specified, the reagents used in the gene library construction process were all purchased kit products and self-prepared reagents.

[0116] The construction of the gene library includes the following steps:

[0117] 1. Genome fragmentation: Take 20 ng of genomic DNA prepared in Example 1, prepare the enzyme digestion reaction system shown in Table 1, shake and mix, centrifuge (avoid bubbles), and then react according to the procedure in Table 2. The concentration of human genomic DNA in this example is 2 ng / μL, and 10 μL needs to be added to the reaction system to obtain a terminal treatment reaction mixture.

[0118] Table 1.

[0119] DNA shearing reaction system Genomic DNA 10μL Breaking enzyme 3μL Buffer 7μL Nucleic acid-free water Make up to 35 μL

[0120] Table 2.

[0121]

[0122] 2. Adapter ligation reaction: 15 μL / sample adapter ligation premix (15 μL / sample, purchased from NEB, item number E7645S) and adapter ligation enhancer (0.5 μL / sample, purchased from NEB, item number E7645S) were pipetted in appropriate volumes according to the number of samples to be tested, and 15.5 μL was pipetted into the terminal treatment reaction mixture (35 μL) in the previous step, and then 1.5 μL of adapter was pipetted into the above reaction solution ...

[0123] Table 3.

[0124] Adapter ligation reaction system End repair reaction mixture (previous step) 35μL Connector connection master mix 15μL Joint Enhancer 0.5μL Mixing joints 1.5μL Overall system 52μL

[0125] Place the above system in a PCR instrument and run the program: 20°C, 30 min, with the hot cover closed to obtain the adapter ligation reaction solution.

[0126] 3. Purification steps after ligation reaction:

[0127] a. Take out the library purification magnetic beads from the magnetic bead kit in advance, let them stand at room temperature for at least 30 minutes, and mix them before use.

[0128] b. Transfer the adapter ligation reaction solution in step 2 above to a 1.5 mL centrifuge tube with the corresponding number, add 46 μL of resuspended library purification magnetic beads, use a pipette of appropriate range to pipette 20 times at a uniform speed, and incubate at room temperature for 5 min.

[0129] c. Place the centrifuge tube on a magnetic rack and discard the supernatant after the solution becomes clear.

[0130] d. Add 200 μL of freshly prepared 80% ethanol, let it stand for 30 seconds, and then discard the supernatant.

[0131] e. Repeat step d once.

[0132] f. Remove the centrifuge tube from the magnetic rack, centrifuge for 3 seconds, put the centrifuge tube back on the magnetic rack, and discard the remaining 80% ethanol. Be careful not to absorb the magnetic beads. Open the tube cover and dry it at room temperature for 2-10 minutes.

[0133] g. When the magnetic beads turn matte, add 16 μL Low TE buffer to the centrifuge tube, shake gently to resuspend the magnetic beads, and incubate at room temperature for 5 minutes.

[0134] h. Place the centrifuge tube on a magnetic rack and let it stand for 2 minutes. After the solution is clarified, take 15 μL of the supernatant (i.e. the purified product after the adapter connection) for the next amplification reaction.

[0135] 4. PCR amplification: Add the corresponding reagents to the PCR tube according to Table 4 below:

[0136] Table 4.

[0137] PCR reaction system Connector ligation purified product 15μL PCR Amplification Enzyme Master Mix 25μL Primer N7XX 5μL Primer N5XX 5μL Overall system 50μL

[0138] Primers N7XX and N5XX were purchased from the TruePrepIndex Kit V2 for Illumina produced by Nanjing Novogene Biotech Co., Ltd. The functions of primers N7XX and N5XX include two aspects: on the one hand, they contain complementary sequences of sequencing primers for subsequent sequencing; on the other hand, they contain a specific sequence as a special marker for samples, which is used to split sample data after sequencing.

[0139] Place the mixed PCR tube into the PCR instrument and run the program according to Table 5:

[0140] Table 5.

[0141]

[0142]

[0143] 5. Purification of PCR products: Refer to step 3 for purification steps, where:

[0144] The amount of library purification magnetic beads resuspended in step b is 22.5 μL;

[0145] In step g, the amount of Low TE buffer (or nuclease-free water) added is 31 μL;

[0146] Take 30 μL of the supernatant in step h and save it for the next step.

[0147] 6. Library quantification on the machine

[0148] The purified library was analyzed for fragment size using the Agilent BioAnalyzer biochip analysis system. The dsDNA HS Assay Kit was used to measure the library mass concentration, and the library molar concentration was calculated by mass concentration and fragment size. The sequencing was performed using Illumina Hiseq X-ten according to the sequencer instructions. The sequencing data was aligned using BWA software. After alignment, the chromosome variation was analyzed using CNVkit to obtain the chromosome analysis results. The point mutation was analyzed using GATK software to obtain the gene mutation analysis results, and the two results were combined for judgment.

[0149] In the present invention, the "fragment size" refers to the number of base pairs contained in the library.

[0150] In the present invention, the "library mass concentration" refers to the mass of the library contained in a unit volume.

[0151] In the present invention, the calculation method of "library molar concentration" refers to library mass concentration / library molecular weight.

[0152] Example 1 A pancreatic cancer detection kit and population diagnostic effect verification

[0153] The kit of this embodiment is used to detect 18 targets, consisting of 1q, 3p14.3-3p26.2, 3q24-3q29, 4p, 6p22.1-24.3, 6q, 7p, 8p, 8q, 9p, 9q, 12p, 12q23.2-12q24.33, 13q, 17p, 18q, 20p11.23-20p13 and KRAS.

[0154] 3p14.3-3p26.2 refers to the area between 3p14.3 and 3p26.2.

[0155] The naming convention of chromosomes in the present invention is chromosome number + chromosome arm + region number + band number.subband, such as 1q represents the long arm of chromosome 1, and 3p14.3 represents the short arm of chromosome 3, region 1, band 4, and subband 3.

[0156] The ranges of the long arm, short arm, region, band, and subband are defined in accordance with the International Rules for Human Chromosome Nomenclature (ISCN) standards. The length information of the chromosome instability-related targets is as follows:

[0157] Chromosomal targets Coverage area length 1q 125Mb 3p14.3-3p26.2 55Mb 3q24-3q29 55Mb 4p 50Mb 6p22.1-24.3 23Mb 6q 110Mb 7p 60Mb 8p 45Mb 8q 100Mb 9p 44Mb 9q 95Mb 12p 35Mb 12q23.2-12q24.33 32Mb 13q 97Mb 17p 25Mb 18q 62Mb 20p11.23-20p13 21Mb

[0158] The point mutations corresponding to the KRAS gene (expressed in amino acid code) include: p.G12D, p.G12V, p.G12R, p.G12C, p.G12A, p.G12S, p.G13D, p.Q61H, p.Q61R, p.Q61L. The geneID of the sequence of the KRAS gene in NCBI is 3845, and the description of the above point mutations refers to the database Catalogue of Somatic Mutation In Cancer (COSMIC).

[0159] The kit of this embodiment may include all reagents or key reagents in Basic Examples 1-2. Those skilled in the art may routinely select each reagent based on Basic Examples 1-2 and the kit of this embodiment.

[0160] As an example, a kit is provided with the following composition:

[0161] Components Main ingredients Fragmentation Enzyme Mix DNA restriction endonucleases Fragmentation Buffer <![CDATA[Tris-HCL,MgCL2,DTT]]> Endoenzyme Mix DNA polymerase, polynucleotide kinase End-repair buffer <![CDATA[Tris-HCL,MgCL2,DTT,dNTPs]]> Ligase DNA ligase Ligation Buffer <![CDATA[Tris-HCL,MgCL2,DTT,PEG6000]]> Connectors Synthesize adapters based on nucleotide sequences PCR Amplification Master Mix <![CDATA[DNA polymerase, dNTPs, MgCL2]]> Negative Control Cell line DNA Positive Control Cell line DNA Purification Magnetic Beads Magnetic beads, buffer

[0162] The clinical samples were tested according to the method of Basic Example 1-2.

[0163] Clinical samples were collected from 137 pancreatic cancer patients (diagnosed according to the 2022 edition of the Pancreatic Cancer Diagnosis and Treatment Guidelines issued by the National Health Commission, and confirmed by surgery and pathology) and 41 non-tumor patient samples, mainly including pancreatitis, pancreatic cysts, benign pancreatic masses, etc.

[0164] The main purpose of setting up these non-tumor patient samples is that it is clinically necessary to perform differential diagnosis between the above-mentioned benign lesions and pancreatic cancer. By adding patients with benign diseases rather than healthy people, the accuracy of the detection method of the present invention in actual clinical use can be better reflected. For example, the prior art has disclosed that pancreatitis is a common misdiagnosed disease of pancreatic cancer (Li Zhaoshen, He Jia. Analysis of misdiagnosed factors of pancreatic cancer [J]. Journal of PLA Medicine, 2002, 27 (4): 3. DOI: 10.3321 / j.issn: 0577-7402.2002.04.009.), and also disclosed the misdiagnosis of pancreatic cysts (Zhang Li, Zhu Gaoming, Jin Zhuoying. Analysis of the causes of easy misdiagnosis of pancreatic cancer (with 101 case reports) [J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2001,

[0165] 8(5):2.DOI:10.3969 / j.issn.1005-8664.2001.05.033.), and also disclosed that when judging the performance of pancreatic cancer diagnostic markers, benign pancreatic masses are used for comparison (Shen Xiangguo. Expression of PD-L1 in peripheral blood and tumor tissue of pancreatic cancer [D]. Naval Medical University of the Chinese People's Liberation Army [2024-05-20].DOI:CNKI:CDMD:2.1018.311952.). It is known in the art that pancreatitis, pancreatic cysts, and benign pancreatic masses are likely to affect the judgment of the results in the diagnosis of pancreatic cancer. Even if markers with diagnostic value are used, they still have a great impact on the results. This is also reflected in some of the documents cited in the present invention, such as: "Chen Xingling, Zhu Xuan, Zhang Kunhe. The diagnostic value of K-ras gene point mutation for pancreatic cancer [J]. Gastroenterology, 2003,

[0166] 8(4):3.DOI:10.3969 / j.issn.1008-7125.2003.04.005”.

[0167] Results Analysis and Discussion:

[0168] After the sequencing data is subjected to the data analysis method described in the present invention (refer to the basic embodiment), a chromosome sequencing depth distribution map is obtained. As an example, the following is provided: Figure 1-Figure 9 It is convenient for those skilled in the art to understand.

[0169] The analysis results are composed of two parts: chromosome variation and gene variation:

[0170] (1) The interpretation of chromosome mutation results includes:

[0171] A. Chromosome numbering and partitioning, for example Figure 1 The lower area in the figure is a schematic diagram of chromosomes, including chromosome numbers and specific partitions;

[0172] B. Chromosome sequencing depth distribution, for example Figure 1 The dots in the chromosome sequencing depth distribution area represent the copy number distribution of small chromosome regions. In the present invention, the dots represent 100kb regions on chromosomes; the mean of the dot array is the midline (the red straight line in the figure), and the value of the corresponding vertical axis coordinate is the Zscores value; the region where the midline continues without breaking is the same variant region.

[0173] According to the content of AB, those skilled in the art can know from the analysis results that the vertical position area corresponding to each chromosome number in the dot matrix represents the distribution of the number of copies of the small chromosome area of ​​the number. Figure 1The mean of the dots in the dashed box is the red straight line, and its corresponding Z value is less than -3 on the ordinate. The corresponding chromosome region below the dots in the dashed box is 3p14.3-3p26;

[0174] The determination of whether a chromosome is stable or not is based on the data analysis results and is specifically determined as follows:

[0175] When the copy number of all chromosomal regions corresponding to the chromosome is between -3 and 3 on the vertical axis, it is determined that no instability occurs;

[0176] When the copy number of all chromosomal regions corresponding to the chromosome is greater than 3 on the vertical axis score, it is judged to be amplified;

[0177] When the copy number of all small chromosomal regions corresponding to the chromosome is less than -3 on the vertical axis, it is judged as missing;

[0178] As per Figure 1 It can be seen that the red line corresponding to the 3p14.3-3p26.2 region on the vertical axis is the Z value. Figure 1 A Z value of less than -3 indicates a deletion in the 3p14.3-3p26.2 region;

[0179] The chromosome combinations that need to be judged in the present invention are: 1q, 3p14.3-3p26.2, 3q24-3q29, 4p, 6p22.1-24.3, 6q, 7p, 8p, 8q, 9p, 9q, 12p, 12q23.2-12q24.33, 13q, 17p, 18q and 20p11.23-20p13.

[0180] The analysis results are used to check whether chromosomal instability (including amplification or deletion) occurs in the chromosome combination that needs to be judged. If it occurs, it is judged as a tumor risk. If not, it is judged as a non-tumor risk.

[0181] (2) Gene mutation: Detection of KRAS gene mutations includes mutations at the three amino acid positions G12, G13, and Q61 in the amino acid sequence encoded by the KRAS gene. When the mutation frequency of any amino acid exceeds 1%, it is judged as a tumor; otherwise, it is judged as a non-tumor.

[0182] The mutation occurring at the amino acid position refers to a variation in the base encoding the amino acid, resulting in a change in the amino acid.

[0183] The mutation frequency in the present invention refers to the ratio of the mutated amino acid positions to all amino acid positions.

[0184] For example: G12 refers to a mutation of the G at position 12 in the amino acid sequence encoded by the KRAS gene, including but not limited to mutations such as p.G12D, p.G12V, p.G12R, p.G12C, p.G12A, and p.G12S; G13 refers to a mutation of the G at position 13 in the amino acid sequence encoded by the KRAS gene, including but not limited to mutations such as p.G13D; Q61 refers to a mutation of the Q at position 61 in the amino acid sequence encoded by the KRAS gene, including but not limited to mutations such as p.Q61H, p.Q61R, and p.Q61L.

[0185] The gene mutation is shown in the figure as two bases appearing at one base position, for example Fig.10 In the figure, each long bar represents that the base was detected once. The dotted box indicates that a codon contains 3 bases. The reference base in the middle position is C. Some of the sequencing results are base T, indicating that the base C is compiled into base T. Some sequencing results have no special mark at this position, indicating that the base is the same as the reference base. When the middle base is C, its codon is GGC, encoding amino acid G. When base C mutates to T, the codon becomes GAC, encoding amino acid D.

[0186] The ROC curves obtained from the 18 target diagnostic samples used in this example are shown in FIG. Fig.11 As shown. ROC curve drawing method: calculate the Z value of each patient's chromosomal instability region and the mutation ratio of all KRAS mutation sites respectively, take the maximum Z value of chromosomal instability and the maximum mutation ratio of KRAS mutation of each patient as independent variables, perform Logistic regression on the above two independent variables, calculate the predicted probability value, take the predicted probability value as the independent variable, and the clinical diagnosis result of pancreatic cancer as the dependent variable, draw the ROC curve, and take the value of the independent variable corresponding to the maximum value of the Youden index as the cut-off value. Fig.11 The results in show that for the pancreatic cancer patient population, the marker combination of the present invention has an AUC value of up to 0.936 when used for diagnosis, which has excellent clinical diagnostic performance. The sensitivity of this example for clinical sample diagnosis is 93.4%, and the specificity is 95.1%.

[0187] Comparative assay marker selection and sample validation

[0188] The same batch of samples was used for detection with reference to Example 1. It should be noted that for the same batch of samples, the actual sequencing results include multiple chromosome loci, so theoretically the same batch of samples can be used to analyze different marker combinations to achieve effect comparison under the same conditions.

[0189] Comparative Examples 1-3 were set up to statistically analyze the sensitivity and specificity of different combinations in pancreatic cancer. The marker combinations and diagnostic results of each comparative example are shown in the following table:

[0190] Table 6.

[0191]

[0192] Analysis of the comparative data shows that the combination of comparative example 1 adds 6 targets relative to the combination of the present invention, and its sensitivity does not change, but the specificity is significantly reduced; comparative example 2 reduces 3 targets relative to the combination of the present invention, and its specificity does not decrease, but the sensitivity decreases significantly; comparative example 3 is a target currently reported to be related to pancreatic cancer, and its sensitivity and specificity are significantly lower than the target combination of the present invention. From the above data, it can be seen that the detection performance of the combination of the present invention is significantly reduced when the target is increased or reduced, and the performance of the target combination that has been reported is also significantly lower than that of the combination of the present invention. It can be seen that the combination of the present invention obtained by screening has a significant performance advantage, and a simple combination of the reported related targets cannot achieve the corresponding performance.

[0193] The target combination of the present invention was further validated using another group of patients. 63 patients with pancreatic cancer and 38 patients with benign pancreatic lesions (pancreatitis, pancreatic cysts, benign pancreatic masses) were re-collected according to the standards in Example 1 for detection. The sensitivity in the validation group was 93.6% and the specificity was 94.7%.

[0194] The present invention performs data comparison and screening through a large number of samples, and selects target combinations with high incidence rates based on clinical data. The performance of the present invention is significantly better than that of reported target combinations, and both increasing and decreasing targets will affect the detection performance. The combination of the present invention is verified by detecting 63 patients with pancreatic cancer and 38 patients with benign pancreatic lesions, and the sensitivity reaches 93.6% and the specificity reaches 94.7%, indicating that the present invention has good diagnostic performance for pancreatic cancer.

[0195] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A combination of a chromosomal unstable region and a gene mutation, characterized in that: The combination consists of 1q, 3p14.3-3p26.2, 3q24-3q29, 4p, 6p22.1-24.3, 6q, 7p, 8p, 8q, 9p, 9q, 12p, 12q23.2-12q24.33, 13q, 17p, 18q, 20p11.23-20p13 and KRAS.

2. Use of a reagent for detecting the combination of chromosomal unstable regions and gene mutations according to claim 1 in the preparation of a reagent or kit for detecting, screening, diagnosing or evaluating the prognosis of pancreatic cancer.

3. A kit for detecting, screening, diagnosing or evaluating the prognosis of pancreatic cancer, characterized in that: The kit comprises reagents for detecting the combination of the chromosomal unstable region and gene mutation as claimed in claim 1.

4. The kit according to claim 3, characterized in that The kit comprises reagents for constructing a sequencing library; the reagents for constructing a sequencing library are selected from one or more of a buffer, an enzyme, a library connector, a nucleic acid extraction reagent, and a nucleic acid purification reagent.

5. The kit according to claim 4, characterized in that The kit includes one or more of a positive reference and a negative reference; the positive reference is a cell line mixed with the chromosomal unstable region and gene mutation described in claim 1; the negative reference is a cell line without chromosomal variation and gene mutation.

6. The kit according to claim 3, characterized in that The sample to be tested is selected from one or more of pancreatic cyst fluid, fresh pancreatic tissue, paraffin sample of pancreatic tissue, bile, and cell sample.

7. The kit according to any one of claims 3 to 6, characterized in that The detection method of the chromosomal unstable region and gene variation is selected from one or more of the second generation sequencing, chip method, comparative genomics, third generation sequencing, and fourth generation sequencing.

8. The kit according to claim 7, characterized in that The method for detecting chromosomal unstable regions and gene mutations is second-generation sequencing.

9. Use of the combination of chromosomal unstable regions and gene mutations according to claim 1 in the preparation of drugs for treating or assisting in the treatment of pancreatic cancer.

10. The use according to claim 9, characterized in that: The dosage form of the medicine is powder, tablet, pill, granule, capsule, solution, emulsion, suspension or oil.